Related Experiment Video

Updated: Feb 9, 2026

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.5K

Anticancer Effects of Dihydroartemisinin on Human Esophageal Cancer Cells In Vivo

Cailing Jiang1, Shumin Li2, Yanjing Li2

  • 1The Oncology Department, The Affiliated Hospital of Guilin Medical University, Guilin 541000, China.

Analytical Cellular Pathology (Amsterdam)
|June 12, 2018
PubMed

Insights

Dihydroartemisinin (DHA) effectively inhibits esophageal cancer growth in vivo by inducing apoptosis. This study highlights DHA as a potential therapeutic agent for improving patient survival rates in esophageal cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Esophageal cancer survival rates remain low despite current treatments.
  • Dihydroartemisinin (DHA), a derivative of artemisinin, shows potential anticancer properties.
  • The precise mechanism of DHA's action in esophageal cancer requires further elucidation.

Purpose of the Study:

  • To investigate the in vivo efficacy of Dihydroartemisinin (DHA) against esophageal cancer.
  • To explore the underlying mechanisms of DHA's anti-cancer effects in vivo.
  • To evaluate DHA as a potential therapeutic agent for esophageal cancer.

Main Methods:

  • In vivo xenograft models using human esophageal cancer cell lines (Eca109 and Ec9706).
  • Administration of Dihydroartemisinin (DHA) at varying doses.
  • Assessment of tumor proliferation inhibition and induction of apoptosis.

Main Results:

  • Dihydroartemisinin (DHA) significantly inhibited tumor cell proliferation in vivo.
  • DHA treatment led to a dose-dependent induction of apoptosis in esophageal cancer cells.
  • These effects were observed in both Eca109 and Ec9706 human esophageal cancer cell lines.

Conclusions:

  • Dihydroartemisinin (DHA) demonstrates significant anti-proliferative and pro-apoptotic effects on esophageal cancer in vivo.
  • DHA shows promise as a novel therapeutic agent for clinical treatment of esophageal cancer.
  • Further research into DHA's mechanism and clinical application is warranted.

More Related Videos

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.2K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.2K

Related Concept Videos

Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
1.5K
Esophageal Perforation-I: Introduction01:22

Esophageal Perforation-I: Introduction

Esophageal perforation is a severe medical condition characterized by a breach in the integrity of the esophageal wall. This breach can occur due to various factors such as trauma, medical procedures, or underlying diseases. When the esophageal wall is compromised, it allows food, fluids, and digestive juices into the chest cavity or adjacent structures, leading to potential complications and health risks.
The location of esophageal perforation can vary, occurring anywhere along the esophagus....
619
Esophageal Strictures-I: Introduction01:30

Esophageal Strictures-I: Introduction

Esophageal strictures involve abnormal narrowing or tightening of the esophagus. They vary in length and severity, ranging from mild constriction to complete obstruction, and are classified as benign (noncancerous) or malignant (cancerous).
Etiology
The primary cause of esophageal strictures is long-standing gastroesophageal reflux disease (GERD), accounting for about 70 to 80% of adult cases. Chronic acid reflux can lead to injury and scarring of the esophageal lining, culminating in...
893
Esophageal Strictures-II: Clinical Features and Management01:26

Esophageal Strictures-II: Clinical Features and Management

Patients with esophageal strictures often experience a range of symptoms. Initially, they may have difficulty swallowing solid foods, which can progress to include liquids. Additional symptoms may involve chest pain or discomfort, regurgitating food and fluids, heartburn, unintentional weight loss, coughing or choking during meals, and hoarseness.
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
688
Esophageal Perforation-II: Clinical Manifestations and Management01:28

Esophageal Perforation-II: Clinical Manifestations and Management

Esophageal perforations manifest in various clinical forms, influenced by factors such as the perforation's cause and location (cervical, intrathoracic, or intra-abdominal), the extent of contamination, and potential injury to adjacent mediastinal structures. The timing between the perforation occurrence and treatment initiation also affects the clinical presentation.
Clinical Manifestations:
741
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
597